In this issue of Dermatology Times, we discuss the impact of disease burden on patients with a variety of dermatologic conditions, including atopic dermatitis, rosacea, psoriasis and more. While room for improvement exists in patient satisfaction, the therapeutic pipeline in these areas is strong and encouraging. We hope that the reports in this issue on drug development in these areas as well as recent clinical guidelines provide you a basis for continuing to improve your care of patients with these conditions.
 
Dermatology Times cover
Atopic dermatitis pipeline full of potential
Atopic dermatitis therapy is currently undergoing a revolution that promises to treat patients of all ages who are suffering from every aspect of the disease—from rashes, itch and sleep disturbances, to secondary effects, like anxiety and depression.

Doxycycline plus topical effective for severe acne
A 40mg doxycycline dose with a topical containing adapalene 0.3% and benzoyl peroxide 2.5% is an effective and safe treatment option for severe acne, according to a single-center pilot study published recently.
Topical rosacea cream creates new treatment paradigm
Topical ivermectin cream, 1% (Soolantra, Galderma) represents an advance in treatment for rosacea, offering superior efficacy and tolerability compared with previously available therapies, says Jeffrey S. Fromowitz, M.D., who spoke at the Orlando Dermatology Aesthetic & Clinical Conference.
Standard of care for primary cutaneous melanoma evolves
Though still considered controversial, several evolving treatment and management plans for primary cutaneous melanoma are making their way into the mainstream and challenging more traditional approaches.

Connect with us on Twitter and Facebook for daily updates.